Biodexa Pharmaceuticals Presents 12-Month Phase 2 Clinical Trial Results Of ERapa In Familial Adenomatous Polyposis To Be Presented At The Biennial InSIGHT 2024 Meeting
Biodexa Pharmaceuticals Presents 12-Month Phase 2 Clinical Trial Results Of ERapa In Familial Adenomatous Polyposis To Be Presented At The Biennial InSIGHT 2024 Meeting
Twelve month Phase 2 Clinical Trial Results of eRapa in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona
eRapa在家族性腺瘤性息肉(FAP) 12個月 II期臨床試驗結果將在2024年巴塞羅那著名的InSIGHT 2024會議上進行介紹。
Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces that 12 month data of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis ("FAP") are to be presented at the prestigious biennial InSIGHT 2024 meeting in Barcelona, Spain on June 22, 2024. Carol Burke, MD, the Principal Investigator, will present the six and 12 month data (NCT04230499) in an oral presentation at the meeting. Dr Burke presented the six-month data at the Digestive Disease Weekly meeting in Washington D.C. on May 21, 2024.
Biodexa藥品公司（NASDAQ:BDRX）是一家專注於收購、開發創新產品以治療未滿足醫療需求的疾病的臨床階段生物製藥公司，宣佈將於2024年6月22日在西班牙巴塞羅那舉行的著名的InSIGHT 2024會議上介紹家族性腺瘤性息肉(FAP) eRapa II期臨床試驗12個月的數據（NCT04230499）。主研醫生Carol Burke將在會議上進行口頭報告，介紹6個月和12個月的數據。Burke博士已於2024年5月21日在華盛頓特區舉行的消化疾病週報告中介紹了6個月的數據。
譯文內容由第三人軟體翻譯。